IC
CABA icon

Ikarian Capital’s Cabaletta Bio CABA Stock Holding History

Ikarian Capital’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-200,000
Closed -$3.41M – 125
2024
Q1 		$3.41M Hold
200,000
– – 0.37% 66
2023
Q4 		$4.54M Buy
+200,000
New +$3.36M 0.43% 61

Other funds holding CABA

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ikarian Capital's CABA Position: Q1 2026 in Review

Ikarian Capital held its Cabaletta Bio (CABA) position steady in Q1 2026 at 900,000 shares worth $2.42M. The position accounts for 0.2% of the portfolio, ranked #89.

Ikarian Capital first reported a position in CABA in Q1 2021 and has held it in 11 quarters since. The position peaked at $14.4M in Q3 2021. 108 funds tracked by Wall St. Rank hold CABA as of Q1 2026.

  • Ikarian Capital held 900,000 shares of Cabaletta Bio worth $2.42M as of Q1 2026.
  • Ikarian Capital left its Cabaletta Bio share count unchanged in Q1 2026.
  • Cabaletta Bio made up 0.2% of Ikarian Capital's portfolio in Q1 2026, its #89 holding.
  • Ikarian Capital first reported a position in Cabaletta Bio in Q1 2021 and has held it in 11 quarters since.
  • Ikarian Capital's Cabaletta Bio position peaked at $14.4M in Q3 2021.
  • 108 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.